| Source: |
| Type: |
| The Wnt signaling pathway is a complex network of proteins that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. It is particularly important during embryonic development and tissue homeostasis. Dysregulation of the Wnt pathway has been implicated in various cancers, making it a significant area of research in oncology. Wnt Ligands Wnt1: Often overexpressed in breast cancer and some types of leukemia. Wnt Receptors Frizzled (Fzd) Receptors: Different Fzd receptors (e.g., Fzd1, Fzd2, Fzd7) have been implicated in various cancers: Fzd1: Overexpressed in colorectal cancer. Fzd2: Associated with breast cancer and prostate cancer. Fzd7: Linked to gastric cancer and glioblastoma. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 123- | CUR, | Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells |
| - | in-vitro, | Colon, | LoVo | - | in-vitro, | Colon, | COLO205 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | 22Rv1 |
| 124- | CUR, | Curcumin-Gene Expression Response in Hormone Dependent and Independent Metastatic Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 3369- | QC, | Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects |
| - | Review, | Pca, | NA |
| 5123- | Sal, | Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HEK293 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:377 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid